BC Innovations | May 11, 2018
Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
BC Week In Review | Jun 28, 2010
Clinical News

Macugen pegaptanib: Phase III data

In the double-blind, international Phase III Study A5751013 trial in 260 patients, 0.3 mg intravitreal Macugen every 6 weeks met the primary endpoint of a significantly greater proportion of patients who gained >10 letters on...
BC Week In Review | Jun 7, 2010
Clinical News

Macugen pegaptanib: Phase IV data

In the prospective, open-label Phase IV LEVEL trial in 568 patients, maintenance therapy with 0.3 mg intravitreal Macugen every 6 weeks for 48 weeks preserved mean visual acuity of 61.8 letters at week 54. Mean...
BioCentury | Mar 8, 2010
Strategy

OSI's Last Stand

OSI Pharmaceuticals Inc. has made two strategic decisions in the last five years that investors didn't like. As a result, it would not be surprising if they refuse to back the company's independence following last...
BC Week In Review | Feb 8, 2010
Clinical News

Macugen pegaptanib: Phase IV data

In an open-label, uncontrolled, U.S. Phase IV trial in 20 patients, Macugen led to a mean gain of 14 letters from baseline to week 54 in BCVA score. Macugen also decreased center point thickness by...
BC Week In Review | Oct 26, 2009
Clinical News

Macugen pegaptanib: Phase I/II data

Data from an open-label Phase I/II trial in 19 patients showed that 0.3 mg intravitreal Macugen every 6 weeks for 30 weeks met the primary endpoint of complete regression of proliferative diabetic retinopathy from baseline...
BioCentury | Jun 30, 2008
Strategy

Pfizer’s biotherapeutic pipeline

Pfizer’s biotherapeutic pipeline Product Description Indication Status Rebif interferon beta-1a Recombinant interferon beta-1a targeting type I interferon (IFN) receptor Multiple sclerosis (MS) Mkt Fragmin dalteparin Low molecular weight heparin Prevent deep vein thrombosis (DVT), prevent...
BC Week In Review | Apr 16, 2007
Clinical News

Macugen pegaptanib update

Researchers affiliated with Duke University will conduct the OSIP-sponsored AWARE trial to document treatment patterns and evaluate adverse event profiles for Macugen, Lucentis ranibizumab, Visudyne verteporfin and Avastin bevacizumab based on data collected from Medicare...
BC Week In Review | Aug 14, 2006
Clinical News

Macugen pegaptanib: Phase III halted

OSIP halted an international Phase III trial of Macugen in combination with Visudyne verteporfin photodynamic therapy in 450 patients. This was based on the company's decision to suspend or curtail research activities in eye disease...
BC Week In Review | Jul 3, 2006
Clinical News

Macugen pegaptanib: Phase IV started

The partners started the 54-week, open-label, U.S. Phase IV LEVEL trial in up to 1,000 patients. The trial will evaluate Macugen, given once every 6 weeks, as maintenance therapy for patients who have received prior...
Items per page:
1 - 10 of 22